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Introduction
Alzheimer's disease is a chronic, progressive neurological disorder that causes profound cognitive and behavioral impairments. Alzheimer's disease is the most common cause of dementia in older adults, afflicting approximately 5 million Americans. Genetic, life style, and environmental risk factors for the development of the disease have been identified but the cause of Alzheimer's is not known.
The available treatments cannot modify the course of the disease or provide a cure, they can only provide symptomatic relief, and the prognosis for someone who has Alzheimer's disease is grim; the average life span after diagnosis is 8-10 years. The cost of caring for patients who have Alzheimer's is very high and as the number of people who develop Alzheimer's increases in the next few decades the monetary strain will be significant.
Epidemiology
As with any disease, the incidence and prevalence statistics of Alzheimer's disease are always retrospective, but available evidence clearly shows that it is a very common, very serious, and growing public health care problem. The Centers for Disease Control and Prevention (CDC) estimated that in 2013, five million Americans had Alzheimer's disease. 1 Alzheimer's disease is the 6 th leading cause of death in the United States among all American adults 1 , and it is the most common cause of dementia, accounting for approximately 60%-80% of all cases of dementia. 2 nurseCe4Less.com nurseCe4Less.com nurseCe4Less.com nurseCe4Less.com nurseCe4Less.com 6 Alzheimer's is a disease that primarily afflicts older people. Most cases of Alzheimer's are diagnosed in people who are 60 years or older, and the prevalence of the disease increases with each decade of life, growing to 20%-40% of the population by age 85. 3 Female gender, even given the greater longevity of women, is a risk factor for the development and progression of Alzheimer's disease, 3-5 and Alzheimer's disease is more common in the African American population. 6 
Etiology And Pathophysiology Of Alzheimer's Disease
Exposure to environmental contaminants, specific lifestyle factors and coupled with chronic medical conditions, and genetics are considered to be the three categories of risk factors that contribute to the development of Alzheimer's disease. How and in whom they come together to cause the disease and their relative importance are not known. Age is considered to be the biggest risk factor for Alzheimer's disease.
Environmental Contaminants
Exposure to environmental contaminants such as air pollution, industrial chemicals, metals, and pesticides has been associated with an increased risk for the development of Alzheimer's disease, 7 and many of these are well-known neurotoxins. However, at this time there is no definitive evidence of a cause and effect relationship between exposure to an environmental contaminant and Alzheimer's disease. 7 
Lifestyle and Medical Conditions
Diabetes, hypertension, obesity, sedentary lifestyle, smoking, and many other diseases and lifestyle factors have been identified as possible risk factors for the development of Alzheimer's disease. [8] [9] [10] [11] [12] Traumatic brain injury (TBI) is strongly associated with Alzheimer's disease. 13 
Genetics
It is often noted that Alzheimer's has a strong genetic component. 14 A family history of Alzheimer's disease is a significant risk factor for developing the disease. An individual who has a first-degree relative (i.e., sibling or parent) with Alzheimer's disease has double the risk for Alzheimer's, and the importance of this inherited risk increases as we age the person ages. 14 Late-onset Alzheimer's is the most common form of the disease.
Although genetic risk factors for late-onset Alzheimer's have been identified, how they increase risk is not understood. 14 Genetic risk factors are not present in all patients who have Alzheimer's.
nurseCe4Less.com nurseCe4Less.com nurseCe4Less.com nurseCe4Less.com nurseCe4Less.com Alzheimer's disease causes two distinct pathophysiological changes in the brain: the formation of amyloid plaques and neurofibrillary tangles. 14 These pathological changes cause permanent damage to neurons and synapses and affect three primary ways that neurons maintain their normal functioning and health: communication, metabolism, and repair. 15 The amyloid plaques are essentially comprised of clumps of amyloid-β peptides, protein constituents which are produced by abnormal processing of amyloid precursor protein (APP); APP is part of the cell membrane of neurons but its exact function is not known.
The amyloid plaques damage neuronal synapses, interfere with normal synaptic transmission, and may cause or contribute to inflammation and oxidative damage in the brain. The neurofibrillary tangles are intracellular support structures in the neurons called microtubules that have had a breakdown in a specific protein called tau. The tau protein is essential for maintaining the integrity of the microtubules -and thus the structural soundness of neurons -and when tau is damaged the microtubules are damaged, and the neuron cannot function and will eventually die. 15 The formation of amyloid plaques and neurofibrillary tangles is the hallmark of Alzheimer's disease, but it is not completely clear how these pathological changes can cause the clinical characteristics and the cognitive decline associated with the disease. In addition, these lesions are found in the brains of people who do not have Alzheimer's disease, 15 although the areas of the brain that are affected and the total number of the pathological lesions are different. 3 
Clinical Features Of Alzheimer's Disease
The clinical features of Alzheimer's disease are varied and complex. Although Alzheimer's is a progressive disease for all patients, there can be distinct differences between patients in terms of how they progress. The changes can occur slowly and incrementally but some patients may have periods -plateaus -in which they are stable. Earlyonset Alzheimer's disease takes a more rapidly progressive course.
However, all patients will eventually be unable to socialize or perform self-care. The presentation or progression of Alzheimer's disease is often described as having four stages: pre-clinical, mild, moderate, and severe. 15 Cognitive impairments are the most prominent clinical feature in patients who have Alzheimer's disease, but physical impairments, language, speech, and visuospatial impairments, and significant behavioral and emotional disorders are also common. These can be very disabling in the later stages of the disease and all of them, the cognitive and physical impairments, visuospatial impairments, language/speech disorders, and the behavioral and emotional disorders, profoundly affect quality of life.
Cognitive Impairments
Cognitive impairments are perhaps the most striking feature of Alzheimer's disease. They typically follow a characteristic pattern and begin with memory problems, and memory disorders are one of the most prominent features of Alzheimer's disease. 3 The patient will forget a conversation that she or he recently had. Names and dates and the location of familiar items cannot be recalled. Initially the memory problems of Alzheimer's disease can be relatively mild and ascribed to aging, but eventually it becomes clear to family, friends, and occasionally the patient that this forgetfulness is serious and indicates the presence of a disease process.
The memory impairments of Alzheimer's disease are not like the memory lapses that are associated with aging: they are progressive, they interfere with the activities of daily living, and their presence can be confirmed using a standardized memory test. 3, 15 If the patient's memory capabilities are below a certain point on standardized memory tests, the patient is said to have mild cognitive impairment, a precursor to Alzheimer's disease.
Learning Break:
The term mild cognitive impairment seems at first reading to be imprecise and vague, but there is a diagnostic procedure that is used to define and detect mild cognitive impairment, and this pathology has important prognostic significance. Mild cognitive impairment is considered to represent an early stage in the progression from normal mental status to Alzheimer's disease, 16 and approximately
50% of patients who have mild cognitive impairment will develop
Alzheimer's disease within four years. 3 Difficulties with what are often called higher intellectual functions are also common. 3 Ordinary day-to-day, self-care activities such as dressing, driving, using eating utensils, reading, locating something in the environment, navigating distances or finding one's way from one place to another are affected. A patient may lose the ability to distinguish colors.
Almost anything that requires coordination of the visual field with motor activities can be difficult or impossible to perform. 3, 17 The behavioral and emotional disturbances and personality changes that are associated with Alzheimer's disease can be devastating for the patient and for family members. They also present significant management challenges because they are intimately and inextricably linked to cognitive, physical, language impairments of the disease that are organic in nature and cannot be changed; they are often resistant to treatment; and, they are numerous and complex.
The following list highlights behavioral and emotional disturbances that are common to Alzheimer's disease; however, this list could easily be expanded. 3. The cognitive effects do not occur extensively in the context of delirium.
BEHAVIORAL AND EMOTIONAL DISTURBANCES
4. The cognitive deficits are not better explained by another mental disorder (i.e., major depressive disorder, schizophrenia).
Early Onset Alzheimer's Disease
Most cases of Alzheimer's disease happen to the elderly, but earlyonset Alzheimer's disease accounts for approximately 5.5% -7% of all cases of the disease. 21, 22 Early-onset Alzheimer's disease is typically described as evidence of the disease in people who are under the age of 65, but there is no universally accepted definition for an age cut-off point. 23 Approximately one-half of all cases of early-onset Alzheimer's disease can be considered as inherited. 24 However, although the genetics of this form of the disease is well understood, it is a dominantly inherited disease but not a fully penetrant disease. 25 As mentioned above, the early-onset form of Alzheimer's disease has a more rapidly progressive course, and it appears to affect different areas of the brain than late-onset Alzheimer's disease. 20 The risk 
Treatment Of Alzheimer's Disease
Alzheimer's disease cannot be cured, it can only be managed and doing so is a big challenge. If the patient has no significant comorbidities, the patient will be relatively healthy in the physical sense and will be ambulatory until late in the progression of the disease. But for both patient and the patient's caretakers, the cognitive deficits and the behavioral and emotional issues associated with Alzheimer's disease -which in many instances are inextricably linked -can create enormously frustrating situations.
It is impossible to improve a patient's memory, executive function, language difficulties; cognitive deficits cannot be reversed; the patient's condition always declines; and behavioral and emotional problems will always occur. But with skillful application of environmental and psychosocial interventions and targeted, judicious use of medications, the patient who has Alzheimer's disease can be safely and effectively cared for.
Drug Therapy
Drug therapy for the treatment of Alzheimer's disease is intended to: 1) provide symptomatic relief from the physical and psychological complications; and, 2) slow the progression of the disease and/or alter the pathophysiologic mechanisms of Alzheimer's disease.
Drug therapy for the treatment of Alzheimer's disease will not be discussed in great detail. Medications can be helpful for providing symptomatic relief, slowing the progression (somewhat) of the disease, and addressing the pathophysiological mechanisms of these disease, but drug therapy is considered to be second-line treatment: 27 the preferred approach is environmental and psychosocial interventions. 27 The generic names of drugs are listed first; trade names are in parentheses.
Symptomatic Treatment
A wide variety of medications have been used to provide patients with symptomatic relief from the emotional, physical, and psychological complications associated with Alzheimer's disease including, but not limited to anti-depressants, anti-epileptic drugs, first and secondgeneration anti-psychotics, anti-parkinsonian drugs, anxiolytics, betablockers, calcium channel blockers, hypnotics or soporifics, and tricyclic anti-depressants. [28] [29] [30] [31] [32] While these drugs can and do provide some benefit, the evidence for their effectiveness in treating agitation, depression, psychosis, sleep disturbances, etc., in patients who have Alzheimer's disease is modest or lacking. [27] [28] [29] [30] And although all drugs have a risk-benefit ratio, for some of the aforementioned medications such as the anti-psychotics and the tricyclic anti-depressants, the risks can be significant and they appear to greatly outweigh the benefits for this patient population. 30 
Disease Progression Slowing or Pathophysiology Alteration
The two types of drugs that are used for this purpose are memantine (Namenda) and the acetylcholinesterase inhibitors donepezil (Aricept), Commonly seen side effects of memantine include confusion, constipation, dizziness, and headache. 33 Memanatine is usually dosed once a day and it is available as an oral solution, regular release, and extended release tablets. It is also available as a combination product with donepezil and this combination of memantine and donepezil (Namzaric) has been shown to be helpful. 29 The acetycholinesterase inhibitors function by reversibly inhibiting acetylcholinesterase, the enzyme that is responsible for enzymatic degradation of the neurotransmitter acetylcholine. 36 Alzheimer's disease damages cholinergic neurons thus decreasing the production of acetylcholine, and this process is thought to be in part responsible for some of the clinical signs of Alzheimer's disease. The acetylcholinesterase inhibitors have been reported to provide a mild to moderate level of improvement in cognition and global functioning. 37, 38 There is no evidence that one of these drugs is superior to the other. 37 Commonly seen side effects of therapy with the acetylcholinesterase inhibitors include diarrhea, nausea, and vomiting. 38 have not been shown to have any significant benefit for these patients. 29, 40 Agitation, aggressive behavior, and psychosis are very common in patients who have Alzheimer's disease. Atypical and conventional antipsychotics would seem to be the most intuitive choice in these situations, and these drugs are often used to treat these behaviors in patients who have Alzheimer's disease. 41 However, the antipsychoticsboth atypical and conventional -can have significant side effects, i.e., antipyramidal effects, arrhythmias, hypotension, sedation, and an increased risk for mortality in elderly patients (possibly); the evidence for the effectiveness of these drugs in this clinical situation is modest, at best; and, they may be especially dangerous for elderly patients who have Alzheimer's disease. 42, 43 
Environmental and Psychosocial Interventions
It is recommended that behavioral and environmental approaches should be used to treat neuropsychiatric behavior problems and emotional issues in patients who have Alzheimer's disease. 27  non-pharmacologic interventions have failed;
 the patient has major depression with or without suicidal ideation;
 the patient has a psychosis that is causing great harm or has the potential to do so;
 the patient is very aggressive and may harm him/herself or others.
It is often assumed that the neuropsychiatric behavior problems and the emotional issues that are so distressing and difficult are simply inevitable for patients who have Alzheimer's disease. These problems do occur quite often and Alzheimer's disease is their root cause, but the precipitating cause of agitation, aggression, inappropriate actions and speech, wandering etc., is almost always internal and/or external stimuli that are not obvious to family members, caregivers, and health care professionals. 27, 44 The patient who has Alzheimer's disease has cognitive deficits that affect the patient's ability to cope, communicate, understand the environment, and to provide self-care. These cognitive deficits and language impairments also mean that the patient with Alzheimer's disease cannot express his or her needs or frustrations, and cannot organize an appropriate response to them. These issues combine to place the patient in a tremendous amount of stress, and the patient reacts.
The behavior and the language of someone who has Alzheimer's disease may be difficult and inappropriate, but the patient is usually reacting to an identifiable stressor. Considering neuropsychiatric behavior problems and emotional outbursts as normal for a patient who has Alzheimer's dementia is in one sense treating the patient as less than whole. 
The DICE Method
The optimal approach to neuropsychiatric behavior problems and emotional difficulties can be summarized very simply: make every effort to understand the situation from the patient's point of view.
Kales et al., (2014) note that the ideal approach is "… to conceptualize behaviors as stemming from unmet needs, environmental overload, and interactions of individual, caregiver, and environmental factors." 27 A useful approach that has been developed is called the DICE approach: Describe, Investigate, Create, and Evaluate. 35 The DICE approach is a systematic way of identifying and treating neuropsychiatric behavior problems. It begins with and operates under the assumption that such difficult management issues with patients who Alzheimer's disease are caused by a stressor that can be identified and corrected, and that these issues can be solved with creativity and patience. The steps in the DICE method are explained below. In the example below, we review a patient exhibiting agitation but the DICE approach can be used for any problem that may arise between an Alzheimer's patient and caregiver. In addition, the DICE approach can be used while an event is happening or retrospectively.
Describe
The staff, family member, or the caretaker reports that the patient has become agitated and aggressive and this behavior is new. In the first step of the DICE approach the clinician, caretaker, or family member should clearly describe the situation; simply reporting that the patient has become agitated and aggressive is not helpful without context. 
Evaluate
In this final step, the creative solution is evaluated for its effectiveness, its negative and positive consequences, and how easy it was to apply. The interventions should also be routinely assessed to ensure they were successful, and if successful, that they are being done correctly.
Can Alzheimer's Disease Be Prevented?
Alzheimer's disease is devastating and there is no cure, so prevention of the disease is an area of intensely focused research. 
Alzheimer's disease is characterized by:
a. cerebral emboli and hyper-coaguability.
b. vasospasm and Lewy bodies.
c. cerebral edema and amyloid plaques.
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